



**BIOPOL CHEMICALS LIMITED**

(Formerly known as Biopol Chemicals Private Limited)

CIN NO. : L20297GJ2023PLC140117

Regd. Office : D-211, 2nd Floor, Block-D, Sumel Business Park-6

Nr. Dudheshwar Circle, Dudheshwar Tavdipura Ahmedabad.

Ahmedabad City, Gujarat - 380004, India

Email id : info@biopolchemicals.com

Contact No. : +91-9147076778

Website : www.biopolchemicals.com

**Date: April 30, 2026**

**To,**  
**Listing Compliance Department**  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E)  
Mumbai – 400 051

**NSE SYMBOL: BIOPOL**  
**ISIN: INE0XW001014**

**Ref: Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Subject: Outcome of Meeting of Board of Directors held today i.e. Thursday, April 30, 2026 for consideration and approval of Audited Financial Results for the Half Year and Year ended on March 31, 2026**

Dear Sir/Madam,

Pursuant to the provisions of Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), we wish to inform you that the Board of Directors of **Biopol Chemicals Limited** at its meeting held today, i.e., Thursday, April 30, 2026, inter alia, has considered and approved the following:

**1. Audited Financial Results:**

The Board has approved the Audited Standalone Financial Results of the Company for the half year and financial year ended March 31, 2026, along with the Audit Report issued by the Statutory Auditors.

We hereby confirm that M/s. MB Jajodia & Associates, Chartered Accountants (Firm Registration No. 0139647W), Statutory Auditors of the Company, have issued an Audit Report with an unmodified opinion on the aforesaid financial results.

In terms of Regulation 33(3)(d) of the SEBI LODR Regulations, the declaration regarding unmodified opinion and Audited Financial Results for the, half year and Year ended on March 31, 2026 is enclosed herewith (as Annexure-A) for your information and record.

**2. Confirmation regarding Large Corporate Criteria:**

We hereby confirm that the Company does not fall under the category of ‘Large Corporate’ as per the applicability criteria specified under SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, read with SEBI Circular No. SEBI/HO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023, for the financial year ended March 31, 2026.



# BIOPOL CHEMICALS LIMITED

(Formerly known as Biopol Chemicals Private Limited)

CIN NO. : L20297GJ2023PLC140117

Regd. Office : D-211, 2nd Floor, Block-D, Sumel Business Park-6

Nr. Dudheshwar Circle, Dudheshwar Tavdipura Ahmedabad.

Ahmedabad City, Gujarat - 380004, India

Email id : [info@biopolchemicals.com](mailto:info@biopolchemicals.com)

Contact No. : +91-9147076778

Website : [www.biopolchemicals.com](http://www.biopolchemicals.com)

The above matters have been duly approved by the Board of Directors at their meeting which commenced at 11:30 A.M. and concluded at 01:20 P.M.

This intimation is also being made available on the website of the Company at [www.biopolchemicals.com](http://www.biopolchemicals.com).

Kindly please take the information in your records.

Thanking You,

Yours Faithfully,

**For, BIOPOL CHEMICALS LIMITED**

**SANTANU SARKAR**

**Managing Director**

**DIN: 01245213**

**Encl: a/a**



# BIOPOL CHEMICALS LIMITED

(Formerly known as Biopol Chemicals Private Limited)

CIN NO. : L20297GJ2023PLC140117

Regd. Office : D-211, 2nd Floor, Block-D, Sumel Business Park-6

Nr. Dudheshwar Circle, Dudheshwar Tavdipura Ahmedabad.

Ahmedabad City, Gujarat - 380004, India

Email id : info@biopolchemicals.com

Contact No. : +91-9147076778

Website : www.biopolchemicals.com

## Annexure – A

To,  
**Listing Compliance Department**  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E)  
Mumbai – 400 051

**NSE SYMBOL: BIOPOL**

**ISIN: INE0XW001014**

**Subject: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").**

Pursuant to Regulation 33(3)(d) of the Listing Regulations, as amended from time to time, we hereby declare that Statutory Auditor of Biopol Chemicals Limited, M/s, MB Jajodia & Associates, Chartered Accountants (Firm Registration Number: 0139647W), have submitted their Report with unmodified opinion on the Audited Financial Results of the Company for the financial year ended March 31, 2026, as approved by the Board at its Meeting held on April 30, 2026.

Request you to kindly take the same on record.

Thank You.

Yours Sincerely,

**For, BIOPOL CHEMICALS LIMITED**

**SANTANU SARKAR**

**Managing Director**

**DIN: 01245213**

Biopol Chemicals Limited (Formerly known as Biopol Chemicals Private Limited)

Registered Office: D-211, 2 Floor, Block-D, Sumel Business Park-6, Nr Dudheshwar Circle, Ahmedabad, Gujarat, India, 380004

Head Office: Unit no 2ES3B1 2nd Floor Mani Casadona Street No 372 Action Area 1, IIFNewtown Alia University, New Town, North 24 Parganas, New Town, WestBengal, India, 700156

CIN: L20297GJ2023PLC140117

Statement of Audited Financial Results for the Half year and Year Ended 31-Mar-2026

(In Lakhs)

| Particulars  | Half Year Ended |                 |                 | Year Ended      |                 |
|--|-----------------|-----------------|-----------------|-----------------|-----------------|
|  | 31-Mar-2026     | 30-Sep-2025     | 31-Mar-2025     | 31-Mar-2026     | 31-Mar-2025     |
|  | Audited         | Audited         | Audited         | Audited         | Audited         |
| Revenue from Operations  | 4,948.60        | 3,165.73        | 3,384.68        | 8,114.33        | 4,922.13        |
| Other Income   | 12.55           | 10.28           | -               | 22.83           | -               |
| <b>Total Income</b>  | <b>4,961.15</b> | <b>3,176.01</b> | <b>3,384.68</b> | <b>8,137.16</b> | <b>4,922.13</b> |
| <b>Expenses</b>  |                 |                 |                 |                 |                 |
| Cost of Material Consumed  | 2,992.61        | 1,378.11        | 1,408.72        | 4,370.72        | 1,882.72        |
| Purchases of Stock in Trade  | 1,079.35        | 1,078.79        | 1,537.65        | 2,158.14        | 2,478.26        |
| Change in Inventories of Work in Progress, Finished Goods and Stock in Trade | (266.76)        | 47.93           | (146.46)        | (218.82)        | (332.18)        |
| Employee Benefit Expenses  | 96.82           | 82.03           | 52.99           | 178.85          | 103.84          |
| Finance Costs  | 98.65           | 53.43           | 37.61           | 152.08          | 60.47           |
| Depreciation and Amortization Expenses                                       | 6.11            | 3.72            | 3.86            | 9.83            | 9.19            |
| Other Expenses   | 143.13          | 137.40          | 86.60           | 280.53          | 141.78          |
| <b>Total expenses</b>  | <b>4,149.91</b> | <b>2,781.41</b> | <b>2,980.97</b> | <b>6,931.32</b> | <b>4,344.09</b> |
| <b>Profit/(Loss) before Exceptional and Extraordinary Item and Tax</b>       | <b>811.24</b>   | <b>394.60</b>   | <b>403.71</b>   | <b>1,205.84</b> | <b>578.04</b>   |
| Exceptional Item   | -               | -               | -               | -               | -               |
| <b>Profit/(Loss) before Extraordinary Item and Tax</b>                       | <b>811.24</b>   | <b>394.60</b>   | <b>403.71</b>   | <b>1,205.84</b> | <b>578.04</b>   |
| Extraordinary Item   | -               | -               | -               | -               | -               |
| <b>Profit/(Loss) before Tax</b>  | <b>811.24</b>   | <b>394.60</b>   | <b>403.71</b>   | <b>1,205.84</b> | <b>578.04</b>   |
| Tax Expenses   |                 |                 |                 |                 |                 |
| - Current Tax  | 208.09          | 101.43          | 103.91          | 309.53          | 147.78          |
| - Deferred Tax   | (0.84)          | (0.26)          | (0.28)          | (1.10)          | (0.97)          |
| - MAT Credit Entitlement   | -               | -               | -               | -               | -               |
| - Prior Period Taxes   | -               | -               | -               | -               | -               |
| <b>Profit/(Loss) for the Period from Continuing Operations</b>               | <b>603.98</b>   | <b>293.42</b>   | <b>300.09</b>   | <b>897.41</b>   | <b>431.23</b>   |
| Profit/(loss) from Discontinuing Operation (before tax)                      | -               | -               | -               | -               | -               |
| Tax Expenses of Discontinuing Operation                                      | -               | -               | -               | -               | -               |
| Profit/(loss) from Discontinuing Operation (after tax)                       | -               | -               | -               | -               | -               |
| <b>Profit/(Loss) for the period</b>  | <b>603.98</b>   | <b>293.42</b>   | <b>300.09</b>   | <b>897.41</b>   | <b>431.23</b>   |
| <b>Paid-up Share Capital</b><br>(Face Value per Share Rs.10 each)            | 1,080.54        | 791.10          | 791.10          | 791.10          | 791.10          |
| <b>Reserves Excluding Revaluation Reserve</b>                                | -               | -               | -               | 3,911.55        | 567.79          |
| Earnings Per Share (Face Value per Share Rs.10 each)                         |                 |                 |                 |                 |                 |
| - Basic (In Rs)  | 6.18            | 3.71            | 3.07            | 10.83           | 5.45            |
| - Diluted (In Rs)  | 6.18            | 3.71            | 3.07            | 10.83           | 5.45            |



**Notes:-**

|    |  |
|----|--|
| 1  | The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at its Meeting held on April 30, 2026. |
| 2  | As the Company operates in a single business segment, accordingly, the reporting under AS17 "Segment reporting" are Not applicable to the company.   |
| 3  | The Statutory Auditors of the Company have carried out the Audit of the above financial results of the Company and have expressed an unmodified opinion on these results.  |
| 4  | Previous period figures have been re-grouped / re-classified wherever necessary, to conform to current period's classification in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013 effective 1st April 2021.   |
| 5  | As the company is listed on SME Platform of NSE, it has been exempted from the applicability of IND-AS as per the proviso to rule 4 of companies (Indian Accounting Standards) Rules, 2015   |
| 6  | The Financial results have been prepared in accordance with the accounting standard as notified under section 133 of the Companies Act 2013 (Act), read with the relevant rules made thereunder and other accounting principles generally accepted in India.   |
| 7  | The results for the Half Year and year ended March 31, 2026 are available on the National Stock Exchange of India Limited website (URL: <a href="http://www.nseindia.com">www.nseindia.com</a> ) and also on the company's website ( <a href="https://biopolchemicals.com/">https://biopolchemicals.com/</a> ).                                    |
| 8  | There are no investor complaints received/pending as on 31 <sup>st</sup> March, 2026.  |
| 9  | Internal Audit of Financial results for the Half Year ended on 31/03/2026 has been conducted by the Internal Auditor of the Company.   |
| 10 | The figure for the both Half Year ended 31 <sup>st</sup> March, 2026 and 31st March, 2025 are the balancing figures between the audited figures in respect of full financial year and the published audited year to date figures of the relevant financial year.   |

For &amp; On behalf of board of, Biopol Chemicals Limited



**Santanu Sarkar**  
Managing Director  
DIN: 01245213

Place : Ahmedabad  
Date: 30-04-2026

**Biopol Chemicals Limited (Formerly known as Biopol Chemicals Private Limited)**

Registered Office: D-211, 2 Floor, Block-D, Sumel Business Park-6, Nr Dudheshwar Circle, Ahmedabad, Gujarat, India, 380004

Head Office: Unit no 2ES3B1 2nd Floor Mani Casadona Street No 372 Action Area 1, IIFNewtown Alia University, New Town, North 24 Parganas, New Town, WestBengal, India, 700156

CIN: L20297GJ2023PLC140117

Audited Statement of Asset and Liabilities as at 31-Mar-2026

(In Lakhs)

| Particulars   | 31-Mar-2026     | 31-Mar-2025     |
|---|-----------------|-----------------|
| <b>I. EQUITY AND LIABILITIES</b>  |                 |                 |
| <b>(1) Shareholders' Funds</b>  |                 |                 |
| (a) Share Capital   | 1,080.54        | 791.10          |
| (b) Reserves and Surplus  | 3,911.55        | 567.79          |
| (c) Money Received against Share Warrants                               | -               | -               |
| <b>Total</b>  | <b>4992.09</b>  | <b>1,358.89</b> |
| <b>(2) Share application money pending allotment</b>                    | -               | -               |
| <b>(3) Non-current liabilities</b>                                      |                 |                 |
| (a) Long-term Borrowings  | 505.55          | 64.01           |
| (b) Deferred Tax Liabilities (Net)                                      | -               | -               |
| (c) Other Non-current liabilities                                       | -               | -               |
| (d) Long-term Provisions  | 6.77            | -               |
| <b>Total</b>  | <b>512.32</b>   | <b>64.01</b>    |
| <b>(4) Current liabilities</b>  |                 |                 |
| (a) Short-term Borrowings   | 340.94          | 704.52          |
| (b) Trade Payables  |                 |                 |
| Total outstanding dues to Msme  | 18.61           | 14.96           |
| Total outstanding dues to Other than Msme                               | 624.90          | 845.14          |
| (c) Other Current Liabilities   | 48.88           | 32.34           |
| (d) Short-term Provisions   | 439.79          | 147.78          |
| <b>Total</b>  | <b>1,473.12</b> | <b>1,744.74</b> |
| <b>Total Equity and Liabilities</b>                                     | <b>6,977.53</b> | <b>3,167.64</b> |
| <b>II. ASSETS</b>   |                 |                 |
| <b>(1) Non-current assets</b>   |                 |                 |
| (a) Property, Plant and Equipment and Capital WIP and Intangible Assets |                 |                 |
| (i) Property, Plant and Equipment                                       | 1,423.84        | 25.45           |
| (ii) Capital Work-in-progress   | 12.00           | -               |
| (iii) Intangible Assets   | 0.35            | 0.33            |
| (iv) Intangible Assets under Development                                | -               | -               |
| (b) Non-current Investments   | -               | -               |
| (c) Deferred Tax Assets (net)   | 3.65            | 0.91            |
| (d) Long-term Loans and Advances  | 35.90           | -               |
| (e) Other Non-current Assets  | -               | -               |
| <b>Total</b>  | <b>1,475.74</b> | <b>26.69</b>    |
| <b>(2) Current assets</b>   |                 |                 |
| (a) Current investments   | -               | -               |
| (b) Inventories   | 1,960.76        | 1,181.44        |
| (c) Trade Receivables   | 2,778.69        | 1,665.64        |
| (d) Cash and cash equivalents   | 51.84           | 114.83          |
| (e) Short-term Loans and Advances                                       | 482.97          | 72.44           |
| (f) Other Current Assets  | 227.53          | 106.60          |
| <b>Total</b>  | <b>5,501.80</b> | <b>3,140.95</b> |
| <b>Total Assets</b>   | <b>6,977.53</b> | <b>3,167.64</b> |

For &amp; On behalf of board of, Biopol Chemicals Limited

*Santanu Sarkar*Santanu Sarkar  
Managing Director

DIN: 01245213

Place : Ahmedabad

Date: 30-04-2026

Biopol Chemicals Limited (Formerly known as Biopol Chemicals Private Limited)

Registered Office: D-211, 2 Floor, Block-D, Sumel Business Park-6, Nr Dudheshwar Circle,  
Ahmedabad, Gujarat, India, 380004

Head Office: Unit no 2E53B1 2nd Floor Mani Casadona Street No 372 Action Area 1, IIFNewtown Alia University, New  
Town, North 24 Parganas, New Town, WestBengal, India, 700156

CIN: L20297GJ2023PLC140117

Audited Statement Cash Flow for the year Ended 31-Mar-2026

(In Lakhs)

| Particulars   | 31-Mar-2026       | 31-Mar-2025     |
|---|-------------------|-----------------|
| <b>( A ) CASH FLOW FROM OPERATING ACTIVITIES</b>                      |                   |                 |
| Profit Before Tax and Extra ordinary Items                            | 1,205.84          | 578.04          |
| <b>Adjustments for:</b>   |                   |                 |
| Depreciation and Amortisation Expense                                 | 9.83              | 9.19            |
| Finance Costs   | 152.08            | 60.47           |
| Interest Income   | (3.16)            | -               |
| Gratuity Expense  | 1.16              | -               |
| Unrealised Forex Gain   | (3.25)            | -               |
| <b>Operating Profit before working capital changes</b>                | <b>1,362.50</b>   | <b>647.71</b>   |
| <b>Changes in Working Capital</b>                                     |                   |                 |
| (Increase)/Decrease in Trade Receivables                              | (1,109.80)        | (686.03)        |
| (Increase)/Decrease in Inventories                                    | (779.32)          | (568.14)        |
| (Increase)/Decrease in Short Term Loans and Advances                  | (410.53)          | (52.44)         |
| Increase/(Decrease) in other Current Assets                           | (110.47)          | (22.28)         |
| Increase/(Decrease) in Trade Payables                                 | (216.59)          | 466.36          |
| Increase/(Decrease) in other Current liabilities                      | 16.54             | 16.38           |
| <b>Cash (Used in)/Generated from Operating Activities</b>             | <b>(1,247.68)</b> | <b>(198.45)</b> |
| Less :- Income Tax paid(Net)  | (28.92)           | 42.91           |
| <b>Net Cash (Used in)/Generated from Operating Activities</b>         | <b>(1,276.60)</b> | <b>(241.37)</b> |
| <b>Extraordinary items</b>  | -                 | -               |
| <b>Net cash generated from / (used in) Operating Activities.....A</b> | <b>(1,276.60)</b> | <b>(241.37)</b> |
| <b>( B ) CASH FLOW FROM INVESTING ACTIVITIES</b>                      |                   |                 |
| Interest Received   | 3.16              | -               |
| Purchase of Property, Plant and Equipment                             | (1,407.99)        | (2.43)          |
| Purchase of Capital WIP   | (12.00)           | -               |
| Purchase of Intangible Asset  | (0.25)            | -               |
| Increase/(Decrease) in Long Term Loans and Advances                   | (35.90)           | -               |
| <b>Net cash generated from / (used in) Investing Activities.....B</b> | <b>(1,452.98)</b> | <b>(2.43)</b>   |
| <b>( C ) CASH FLOW FROM FINANCING ACTIVITIES</b>                      |                   |                 |
| Proceeds from issue of Share Capital (IPO)                            | 3,125.95          | -               |
| Less:- Issue Cost   | (385.26)          | -               |
| Net Proceeds from issue of Share Capital                              | 2,740.69          | -               |
| Proceeds from Short Term Borrowings                                   | 150.04            | 346.86          |
| Repayment of Short Term Borrowings                                    | (681.25)          | -               |
| Repayment of Long Term Borrowings                                     | (3.72)            | -               |
| Proceeds From Long Term Borrowings                                    | 612.89            | 64.01           |
| Interest and Finance Charges Paid                                     | (152.08)          | (60.47)         |
| <b>Net cash generated from / (used in) Financing Activities.....C</b> | <b>2,666.58</b>   | <b>350.40</b>   |
| <b>Net increase in cash and cash equivalents (A+B+C)</b>              | <b>(62.99)</b>    | <b>106.60</b>   |
| Opening Balance of Cash and Cash Equivalents                          | 114.83            | 8.23            |
| <b>Closing Balance of Cash and Cash Equivalents</b>                   | <b>51.84</b>      | <b>114.83</b>   |



| Components of cash and cash equivalents                     | 31-Mar-2026  | 31-Mar-2025   |
|---|--------------|---------------|
| Cash on hand  | 8.75         | 2.27          |
| Cheques, drafts on hand                                     | -            | -             |
| Balances with banks in current accounts                     | 43.08        | 112.56        |
| Bank Deposit having maturity of less than 3 months          | -            | -             |
| Others  | -            | -             |
| <b>Cash and cash equivalents as per Cash Flow Statement</b> | <b>51.84</b> | <b>114.83</b> |

For & On behalf of board of, Biopol Chemicals Limited



Santanu Sarkar

**Santanu Sarkar**  
Managing Director  
DIN: 01245213

Place : Ahmedabad  
Date: 30-04-2026

Disclosure of Related Party Transactions for the Half Year Ended March 31, 2026

| Sr. No. | Details of the party (listed entity /subsidiary) entering into the transaction |              | Details of the counterparty |     |   | Type of related party transaction | Details of other related party transaction | Value of the related party transaction as approved by the audit committee | Remarks on approval by audit committee | Value of the related party transaction ratified by the audit committee | Date of Audit Committee Meeting where the ratification was approved | Value of transaction during the reporting period | In case monies are due to either party as a result of the transaction |                 | In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments |                               |      |        | Details of the loans, inter-corporate deposits, advances or investments |                   |        |                    |  |       |   |
|---------|--|--------------|-----------------------------|-----|---|-----------------------------------|--|---|--|--|---|--|---|-----------------|---|-------------------------------|------|--------|---|-------------------|--------|--------------------|--|-------|---|
|         | Name   | PAN          | Name                        | PAN | Relationship of the counterparty with the listed entity or its subsidiary |                                   |  |   |  |  |   |  | Opening balance   | Closing balance | Nature of indebtedness (loan/ issuance of debt/ any other etc.)   | Details of other indebtedness | Cost | Tenure | Nature (loan/ advance/ inter-corporate deposit/ investment)             | Interest Rate (%) | Tenure | Secured/ unsecured | Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage) | Notes |   |
|         |  |              |                             |     |   |                                   |  |   |  |  |   |  |   |                 |   |                               |      |        |   |                   |        |                    |  |       |   |
| 1       | Biopol Chemicals Limited   | AALCB 5111 B | Santanu Sarkar              |     | Managing Director   | Remuneration Payable              | 30,00,000.00                               | -   | -                                      | -  | -   | -  | -   | -               | -   | -                             | -    | -      | -   | -                 | -      | -                  | -  | -     |   |
| 2       | Biopol Chemicals Limited   | AALCB 5111 B | Santanu Sarkar              |     | Managing Director   | Unsecured Loan Accepted           | 1,70,00,000.00                             | -   | -                                      | -  | -   | -  | -   | 1,26,14,800.00  | -   | -                             | -    | -      | -   | -                 | -      | -                  | -  | -     | - |
| 3       | Biopol Chemicals Limited   | AALCB 5111 B | Santanu Sarkar              |     | Managing Director   | Unsecured Loan Repaid             | 43,85,200.00                               | -   | -                                      | -  | -   | -  | -   | 1,26,14,800.00  | -   | -                             | -    | -      | -   | -                 | -      | -                  | -  | -     | - |
| 4       | Biopol Chemicals Limited   | AALCB 5111 B | Vandana Vij Sarkar          |     | Spouse of Santanu Sarkar (Salary)   | Remuneration Payable              | 3,00,000.00                                | -   | -                                      | -  | -   | -  | -   | -               | -   | -                             | -    | -      | -   | -                 | -      | -                  | -  | -     | - |
| 5       | Biopol Chemicals Limited   | AALCB 5111 B | Vedant Sarkar               |     | Whole time Director   | Remuneration Payable              | 24,00,000.00                               | -   | -                                      | -  | -   | -  | 11,87,200.00  | 3,03,550.00     | -   | -                             | -    | -      | -   | -                 | -      | -                  | -  | -     | - |
| 6       | Biopol Chemicals Limited   | AALCB 5111 B | Sandip Choudhury            |     | Chief Financial Officer   | Remuneration Payable              | 1,76,700.00                                | -   | -                                      | -  | -   | -  | -   | -               | -   | -                             | -    | -      | -   | -                 | -      | -                  | -  | -     | - |
| 7       | Biopol Chemicals Limited   | AALCB 5111 B | Deepthi Nama                |     | Company Secretary   | Remuneration Payable              | 1,50,000.00                                | -   | -                                      | -  | -   | -  | -   | -               | -   | -                             | -    | -      | -   | -                 | -      | -                  | -  | -     | - |

For & On behalf of board of, Biopol Chemicals Limited



*Santanu Sarkar*  
**Santanu Sarkar**  
 Managing Director  
 DIN: 01245213